New Rochelle, NY, United States of America

Richard Feltenstein

USPTO Granted Patents = 4 

Average Co-Inventor Count = 2.0

ph-index = 3

Forward Citations = 43(Granted Patents)


Company Filing History:


Years Active: 2014-2021

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Richard Feltenstein

Introduction

Richard Feltenstein is an accomplished inventor based in New Rochelle, NY (US). He has made significant contributions to the field of medicine, particularly in the treatment of autism. With a total of four patents to his name, Feltenstein's work focuses on innovative therapeutic approaches that aim to improve the quality of life for individuals with autism.

Latest Patents

One of Feltenstein's latest patents involves the use of lactulose in the treatment of autism. This treatment administers an effective amount of lactulose to bind excess ammonia in the gastrointestinal tract, bloodstream, and nervous system. The goal is to prevent or reverse ammonia poisoning, which can occur due to certain antibiotics. The lactulose molecules are fermented by specific bacteria in the colon, lowering the colonic pH. This process allows ammonia, in the form of ammonium ions, to be utilized by the bacteria for amino acid and protein synthesis. Consequently, this lowers serum ammonia levels and reduces neurotoxicity.

Career Highlights

Feltenstein's career is marked by his dedication to research and innovation in medical treatments. His work has garnered attention for its potential to address complex health issues, particularly in the realm of autism treatment.

Collaborations

Feltenstein collaborates with Joan M. Fallon, further enhancing the impact of his research and innovations in the medical field.

Conclusion

Richard Feltenstein's contributions to the treatment of autism through innovative use of lactulose highlight his commitment to improving health outcomes. His patents reflect a deep understanding of the complexities of medical treatments and the potential for innovation in addressing these challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…